Assessment of Human DNA Vaccine Markets to 2028 by Mode of Administration, Application, End-user and Region

2023-06-23

疫苗临床研究紧急使用授权上市批准

DUBLIN, June 23, 2023 /PRNewswire/ -- The "Human DNA Vaccine Market - Global Industry Size, Share, Trends, Competition, Opportunity, and Forecast, 2018-2028 Segmented By Mode of Administration (Intramuscular, Subcutaneous, Intradermal, Others), By Application, By End User, By Region and Competition" report has been added to

ResearchAndMarkets.com's offering.

The global human DNA vaccine market is anticipated to observe impressive growth during the forecast period, 2024-2028, owing to the growing prevalence of cancer and infectious diseases in humans. An increase in the number of antibiotic-resistant pathogens is further expected to drive the growth of the human DNA Vaccine Market.

The growing prevalence of different diseases has significantly increased the demand for different types of vaccines. Additionally, growing research & development activities being initiated by various governments and pharmaceutical & biotechnology companies across the globe are further expected to create lucrative opportunities for the growth of the human DNA vaccine market in the coming years. In 2021, the research & development expenditure in the pharmaceutical industry across the globe was around USD238 billion.

Rise in Prevalence of Different Diseases

Globally, cancer is the leading cause of death. According to World Health Organization, around 50,550,287 cases of cancer prevalence have been reported worldwide in the last five years. This is due to the physical carcinogens, such as ultraviolet and ionizing radiation; chemical carcinogens, such as asbestos, components of tobacco smoke, alcohol, aflatoxin (a food contaminant), and arsenic (a drinking water contaminant) and biological carcinogens, such as infections from certain viruses, bacteria, or parasites as well as unhealthy lifestyle.

Cancer has become a global healthcare concern. The need to develop therapies for cancer is expected to support the growth of global human DNA vaccine market. Similarly, the increasing prevalence of diseases such as HIV, Human Papillomavirus, and Tuberculosis, which are deadly and require a potential treatment, is further expected to drive the growth of global human DNA vaccine market. As of 2021, globally, around 38.4 million people were living with HIV.

Increase in Number of Antibiotics Resistant Pathogens

Antibiotic resistance is one of the biggest threats to global health, food security, and development. The epidemiological models describe a direct relationship between antibiotic consumption and resistant pathogen. According to World Health Organization, 32 antibiotics were identified in clinical development, which addressed the top priority pathogens.

Some multi and resistant bacteria called "superbugs" that cause infections are not treatable with existing antimicrobial medicines such as antibiotics. Also, certain bacteria have developed resistance to existing treatment options, thereby creating a need to develop novel therapeutic solutions which can address the issue of antibiotic resistance. This, in turn, is expected to fuel the growth of Global Human DNA Vaccine Market.

Growth in R&D for DNA Vaccine

Rapid advancements in research and development (R&D) practices and activities are propelling the growth of the market on account of the growing need to develop novel human vaccines for the treatment of different life-threatening diseases. According to Clinicaltrials.gov, 247 clinical trials are in different phases of development across the globe for Human DNA vaccines. This clearly indicates that a lot of R&D is being done across the globe for developing human DNA vaccines for the treatment of different diseases, thereby supporting the growth of the global human DNA vaccine market.

Recent Developments

ZyCoV-D is a DNA plasmid-based COVID-19 vaccine COVID-19 vaccine developed by Indian pharmaceutical company Cadila Healthcare, with support from the Biotechnology Industry Research Assistance Council in August 2021. This vaccine illustrated higher safety, efficacy, and immunogenicity.

The vaccine is administered into the skin without an injection and has been found to be 67% protective against symptomatic COVID-19 in clinical trials. ZyCoV-D is a three-dose intradermal vaccine applied using The PharmaJet needle-free system, Tropis, which can significantly reduce any side effects and improve quality. Zydus Cadila Zydus Cadila has received approval for Emergency Use Authorization (EUA) from the Drug Controller General of India (DCGI) for ZyCoV-D.

Report Scope

In this report, Global Human DNA Vaccine Market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below.

Human DNA Vaccine Market, by Mode of Administration

Intramuscular

Subcutaneous

Intradermal

Others

Human DNA Vaccine Market, by Application

Oncology

Tuberculosis

HIV

Human Papillomavirus

Others

Human DNA Vaccine Market, by End-user

Hospitals & Clinics

Biotechnology & Pharmaceutical Companies

Academic & Research Institutions

Others

Human DNA Vaccine Market, by Region

North America

Europe

Asia-Pacific

South America

Middle East & Africa

Competitive Landscape

Detailed analysis of the major companies present in Global Human DNA Vaccine market. A selection of companies mentioned in this report includes:

BOEHRINGER INGELHEIM GmbH (Merial)

ELI-LILLY (Novartis Animal Health)

Gene One Life Science

GEOVAX LABS, INC

Inovio Pharmaceuticals (VGX Animal Health)

Genexine, Inc.

VIATRIS INC. (Rottapharm Biotech)

Takara Holdings (Takara Bio)

ZOETIS INC. (Fort dodge Animal Health)

Zydus Lifesciences Limited

For more information about this report visit https://www.researchandmarkets.com/r/2h19r7

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Research and Markets

Laura Wood, Senior Manager

[email protected]

For E.S.T Office Hours Call +1-917-300-0470

For U.S./CAN Toll Free Call +1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907

Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

SOURCE Research and Markets